Literature DB >> 31367242

Erratum: Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum.

Maximilian Klingler1, Clemens Decristoforo1, Christine Rangger1, Dominik Summer1, Julie Foster2, Jane K Sosabowski2, Elisabeth von Guggenberg1.   

Abstract

[This corrects the article DOI: 10.7150/thno.24378.].

Entities:  

Year:  2019        PMID： 31367242      PMCID： PMC6643442          DOI： 10.7150/thno.36746

Source DB:  PubMed          Journal:  Theranostics        ISSN： 1838-7640            Impact factor:   11.556


In our paper 1 unfortunately an error occurred in Figure 1. We therefore would like to provide the readers with the corrected figure and apologize for this inconvenience.
Figure 1

Structure of A) DOTA-MG11, B) DOTA-MGS1, C) DOTA-MGS2, D) DOTA-MGS3, E) DOTA-MGS4; R = DOTA-DGlu-Ala-Tyr-Gly.

  1 in total

1.  Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.

Authors:  Maximilian Klingler; Clemens Decristoforo; Christine Rangger; Dominik Summer; Julie Foster; Jane K Sosabowski; Elisabeth von Guggenberg
Journal:  Theranostics       Date:  2018-04-16       Impact factor: 11.556
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.